What question did this study set out to answer?

To determine whether acute pre-reperfusion or chronic post-infarction administration of ticagrelor reduces reperfusion injury and improves cardiac remodeling compared to clopidogrel.

June 5, 2015Arteriosclerosis Thrombosis and Vascular BiologyOpen Access

Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction

View Full Paper

Ask AI

Bookmark

Why the study?

Does ticagrelor protect against reperfusion injury and improve heart function compared to clopidogrel after myocardial infarction?

Key Points

To determine whether acute pre-reperfusion or chronic post-infarction administration of ticagrelor reduces reperfusion injury and improves cardiac remodeling compared to clopidogrel.
Administered ticagrelor or clopidogrel acutely immediately prior to reperfusion following myocardial infarction.
Evaluated outcomes under acute administration, chronic 4-week therapy, and combined acute and chronic treatment regimens.
Ticagrelor administered immediately prior to reperfusion prevented reperfusion injury, whereas clopidogrel conferred no cardioprotection despite achieving an equivalent degree of platelet inhibition.
Acute treatment, 4-week chronic therapy, and their combination with ticagrelor each significantly improved cardiac function and remodeling, whereas clopidogrel demonstrated no functional benefit.

Structured PICO

Does ticagrelor protect against reperfusion injury and improve heart function compared to clopidogrel after myocardial infarction?

Population

Myocardial infarction model undergoing reperfusion

Intervention

Ticagrelor (administered acutely just before reperfusion, chronically for 4 weeks, or a combination of both)

Comparator

Clopidogrel (achieving a similar degree of platelet inhibition)

Outcome

Reperfusion injury and heart function/remodelingsurrogate

Ticagrelor offers cardioprotective benefits against reperfusion injury and improves post-MI remodeling independent of its antiplatelet effects, unlike clopidogrel.

Implication

Animal data suggest ticagrelor may limit reperfusion injury; leaves open translation to human MI outcomes.

Abstract

Ticagrelor, but not clopidogrel, administered just before reperfusion protects against reperfusion injury. This acute treatment or chronic ticagrelor for 4 weeks or their combination improved heart function, whereas clopidogrel, despite achieving a similar degree of platelet inhibition, had no effect.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2015) studied this question.

synapsesocial.com/papers/69d570aa75589c71d767de18 https://doi.org/10.1161/atvbaha.115.305655

View Full Paper

Ask AI

Bookmark

Implication

Animal data suggest ticagrelor may limit reperfusion injury; leaves open translation to human MI outcomes.

Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading